Comparing I-PRF and Nano MTA for Pulp Treatment in Molars
Clinical and Radiographic Assessment of I-PRF Versus Nano Mineral Trioxide Aggregate Combined with I-PRF Scaffold in Vital Pulp Therapy in Mandibular First Molars with Closed Apices: "Randomized Controlled Trial"
This study is testing whether a new treatment using I-PRF works better than a combination of Nano MTA and I-PRF for fixing painful tooth pulp in molars.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 51 (estimated) |
| Ages | 15 Years to 30 Years |
| Sex | All |
| Sponsor | Future University in Egypt Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT06640205 on ClinicalTrials.gov |
What this trial studies
This clinical trial assesses the effectiveness of I-PRF (Injectable Platelet-Rich Fibrin) versus Nano Mineral Trioxide Aggregate combined with I-PRF in performing pulpotomy on mature mandibular first molars. The study involves a randomized controlled trial design, focusing on clinical and radiographic outcomes to determine which treatment provides better results for patients suffering from symptomatic irreversible pulpitis. Participants will be monitored for healing and restoration of the affected teeth over a specified follow-up period.
Who should consider this trial
Good fit: Ideal candidates are patients aged 15-30 with symptomatic irreversible pulpitis in mature mandibular first molars that are restorable.
Not a fit: Patients with immature roots, periapical lesions, or necrotic pulp will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve treatment outcomes for patients with irreversible pulpitis in molars, leading to better dental health and preservation of teeth.
How similar studies have performed: While there is ongoing research in the field of pulp therapy, this specific comparison of I-PRF and Nano MTA is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients suffering from Symptomatic irreversible pulpitis in mature mandibular molars only will be involved. * Patients of either gender aged from 15-30. * Tooth should give positive response to cold test. * The tooth is restorable * Patients should be free from any systemic disease that may affect normal healing and predictable outcome. * Patients who will agree to the consent and will commit to follow-up period. * Patients with mature root. * Patients with no internal or external resorption and no periapical lesions. * Soft tissues around the tooth are normal with no swelling or sinus tract. Exclusion Criteria: * Patients with immature roots. * Haemostasias after 10 minutes can not be controlled after total pulpotomy * Patients with periapical lesions or infections. * Pregnant females. * Patients with fistula or swelling * Patients with necrotic pulp.
Where this trial is running
Cairo
- Future university in egypt — Cairo, Egypt (Recruiting)
Study contacts
- Study coordinator: abdelrahman Mo Omar, Master
- Email: Abdulrahmanomar232@gmail.com
- Phone: 00201000424892
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.